Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01773967 · ClinicalTrials.gov registry record · Phase 2
Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 971
- Enrollment target
NCT01773967: Completed Phase 2 study, sponsored by Washington University School of Medicine.
NCT01773967 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 971 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (630% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01773967, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 971 participants
- Enrollment target
Study Summary
The investigators will study the efficacy and side effect profile of LGG, a probiotic, in pediatric patients with acute gastroenteritis.
Primary Outcome
This is a validated gastroenteritis severity score that includes duration and frequency of diarrhea, duration and frequency of vomiting, duration and frequency of fever and use of health care resources. Scores \>=9 indicate moderate-severe gastroenteritis. Higher is worse.
Interventions
- DRUG LGG
- DRUG micro-crystalline cellulose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 971 participants |
| Start Date | 2014-07 |
| Est. Completion | 2018-08 |
| Phase | Phase 2 |
What the finished NCT01773967 record still lists
NCT01773967 is an interventional study that assigns participants to a tested intervention. The registered 971 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (630% higher).
The record links to 0 conditions, and to 2 interventions - of which LGG is the first listed.
NCT01773967 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01773967 about?
NCT01773967 is a clinical study titled "Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis". The investigators will study the efficacy and side effect profile of LGG, a probiotic, in pediatric patients with acute gastroenteritis.
What is the current status of trial NCT01773967?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 971 participants. The study started on 2014-07. Estimated completion is 2018-08.
What interventions are being tested in trial NCT01773967?
The interventions under investigation include: LGG (DRUG), micro-crystalline cellulose (DRUG).
Who is sponsoring clinical trial NCT01773967?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01773967's enrollment target sits among peer trials
971 28th of 2000 higher than 1,973 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05354141 · 970 participants · Phase 3
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
- NCT06948422 · 974 participants · Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
- NCT05600777 · 975 participants · Phase 3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- NCT06541704 · 975 participants · Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia